Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia.

Saved in:
Bibliographic Details
Title: Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia.
Authors: Reeskamp LF; Department of Vascular Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Internal Medicine, OLVG, Amsterdam, the Netherlands., Shim I; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea., Dron JS; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Ibrahim S; Department of Vascular Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands., Tromp TR; Department of Vascular Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands., Fahed AC; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Patel AP; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Hutten BA; Department of Clinical Epidemiology and Data Science, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Stroes ESG; Department of Vascular Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Hovingh GK; Department of Vascular Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.; Novo Nordisk, København, Denmark., Khera AV; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Division of Cardiology and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Verve Therapeutics, Cambridge, Massachusetts, USA.
Source: JACC. Advances [JACC Adv] 2023 Oct 28; Vol. 2 (9), pp. 100662. Date of Electronic Publication: 2023 Oct 28 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918419284106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2772-963X (Electronic) Linking ISSN: 2772963X NLM ISO Abbreviation: JACC Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2772-963X
DOI:10.1016/j.jacadv.2023.100662